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•Aggregation profiles were calculated for Bovine DNase
I, Bovine Insulin, and recombinant human insulin using 
both Aggrescan and SAP. The profiles were normalized 
by the residue’s aggregation propensity with the highest 
magnitude for each protein.
•The aggregation profiles of each protein show similar 
trends overall for both methods
•Any major discrepancies are likely due to differences in 
how the protein is modeled by the computational 
programs. Regions considered aggregation prone by 
Aggrescan may not be  part of the exposed surface area 
and therefore are not considered aggregation prone by 
SAP.
•Aggrescan takes seconds to run through an internet 
browser, while SAP takes anywhere from 10 minutes to 
an hour on a cluster of 16 x AMD 1.2 GHz MP 
processors , depending on protein size.
•Surface Aggregation Potential (SAP) uses the 
hydrophobicity , solvent accessible surface area, and 
proximity of residues in the folded state to determine 
aggregation prone regions or “hot spots”5.
•SAP considers the protein's tertiary structure and 
assumes only the solvent accessible surface area is 
available to interact with other proteins during 
aggregation.
•Aggrescan looks at the amino acid sequences for 
regions (hot spots) where the  amino acids have high 
aggregation propensities6.
•Aggrescan uses experimental data to determine 
aggregation propensities for each residue.
•Aggrescan is only concerned with the primary 
sequence.
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•FTIR experiments are being conducted on protein 
systems previously studied via H/D exchange.
•H/D exchange shows which regions exchange deuterium 
for hydrogen. The exchange regions are exposed and 
should prove to be most susceptible to aggregation7.
•Experiments are also being performed on proteins that 
have had part of their amino acid sequence truncated. The 
FTIR results will be compared to the results of the wild 
type protein to determine how the removed regions affect 
the exposed surface area.
•Further work will compare the exposed regions to the 
predicted aggregation prone regions.
•Proteins can interact with each other through electrostatic 
or hydrophobic/hydrophilic interactions to form bound 
groups called aggregates1.
•Aggregation is a major concern when developing protein 
therapeutics. Significant aggregation can lead to product 
loss and may elicit an immune response in the patient2.
•Aggregation may be limited by the use of excipients in 
the therapeutic formulation. Excipients are molecules used 
as additives in pharmaceuticals3.
•This project is concerned with predicting the aggregation 
of proteins, specifically the regions most prone to 
aggregation. 
•Once the aggregation prone regions are known, 
excipients can be designed that will favorably interact 
with the regions. An ideal excipient will minimize the 
possible interactions between proteins.
•Preliminary experimental data has been collected  for the 
percent aggregation observed in various protein-excipient 
formulations. The excipients considered were 
poly(vinylpyrrolidone) (PVP), trehalose, and guanidine 
hydrochloride.
•The data collected indicates that trehalose is most 
effective in preventing protein aggregation. Sugars, such 
as trehalose, are widely used in practice to stabilize 
protein formulations. Sugars may interact with 
hydrophobic regions on the protein’s surface.
•In industry, trial-and-error approaches  or heuristics are 
often used to determine which excipients are included in 
the pharmaceutical formulation.
•Many common excipients are not effective for many 
emerging biologics and novel drug delivery systems4.
•This project aims to use Computational Molecular 
Design to determine optimal excipients for protein 
formulations.
•Computational Molecular Design is a methodology to 
develop novel structures for molecules based on specific 
physical chemical and biological property targets.
•Models are created to relate properties to the structure of 
known molecules, in this case excipients and proteins. 
•The models used to find optimal molecules that match a 
desired property set. For this project, the optimal 
excipients will be found that minimize protein 
aggregation.
•To use Computation Molecular Design for protein-
excipient systems, aggregation must be modeled.
•Protein aggregation can be computationally modeled 
using Aggrescan and SAP. The prediction will be used to 
create models for designing excipients via Computational 
Molecular Design.
•Aggrescan may work best for a quick view of the 
aggregation tendencies of a protein, especially if many 
different proteins need to be quickly evaluated. SAP can 
be used to provided a more refined estimate of 
aggregation for a protein of interest.
•Molecular simulations will study the interactions of 
proteins and excipients. The regions of  interaction should 
match the predicted aggregation prone regions.
•FTIR analysis will be performed on protein-excipient 
mixtures to determine the excipient’s effect on the 
exposed surface area of the protein.
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